TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33373480
Drug: brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: brodalumab 210 mg Q2W
Study: 34379363
Drug: Participation in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participation in a randomized trial between two treatment durations
Study: 32000725
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) with VR exposure based on 360° videos
Study: 32000725
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) with in vivo exposure
Study: 32000725
Drug: VR relaxation
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR relaxation therapy
Study: 35526272
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing regimen
Study: 34770193
Drug: OHEMA (Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHEMA (Oral Health Education Mobile App)
Study: 33220215
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral iron therapy
Study: 32648810
Drug: brexpiprazole 2–4
Approvals — FDA: no, EMA: no, PMDA: no
Description: brexpiprazole 2–4 mg/day
Study: 32648810
Drug: brexpiprazole 1–4
Approvals — FDA: no, EMA: no, PMDA: no
Description: brexpiprazole 1–4 mg/day
Study: 33713718
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (MWD + CDO)
Study: 38199593
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy
Study: 35184491
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of 20 µg vaccination
Study: 35184491
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of 60 µg vaccination
Study: 35184491
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of 20 µg vaccination
Study: 34499349
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg
Study: 37851095
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: 37917218
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy
Study: 35059864
Drug: Bone-modifying agents
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-modifying agents (BMA)
Study: 32331914
Drug: Injectable antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable antibiotics (primarily penicillins and cephalosporins)
Study: 32331914
Drug: Analgesics and
Normalized name: Analgesics and anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics and insulin
Study: 32331914
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of prescription and injectable drugs
Study: 35447934
Drug: Placebo, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 grams daily for 180 days
Study: 34188114
Drug: Stroke lesions
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke lesions in the right putamen and internal capsules of both hemispheres
Study: 39453400
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment)
Study: 39085322
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment
Study: 33683710
Drug: Midazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2 mg)
Study: 37246259
Drug: Live Attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live Attenuated Influenza Vaccine (LAIV)
Study: 33453140
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)
Study: 32234756
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with gemcitabine (Gem)
Study: 35868334
Drug: Liraglutide (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (one daily subcutaneous injection uptitrated from 0.6-1.8 mg per day over 3 weeks)
Study: 35868334
Drug: Colesevelam (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (three capsules of 625 mg twice daily)
Study: 39023393
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment
Study: 36027558
Drug: Chemotherapy (eribulin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)
Study: 38849734
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg
Study: 38126083
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy
Study: 35246470
Drug: upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 30 mg
Study: 32396038
Drug: Pilates program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates program (36 weeks, twice weekly)
Study: 34172505
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care plus phone-based weekly pill refilling and daily medication reminders
Study: 34551581
Drug: Standard bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bupivacaine (SB) - 60 ml of 0.25% SB
Study: 32920957
Drug: Fortasyn Connect
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortasyn Connect (125 mL once-a-day drink)
Study: 32947496
Drug: Lactic acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic acid (LA) at doses of 30, 60, or 120 mg/mL
Study: 32947496
Drug: Placebo (iohexol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (iohexol, 1.5 mL)
Study: 35041662
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle intervention (increased physical activity, weight loss target 7% through meal replacements and medication Orlistat)
Study: 34925513
Drug: Chest-to-chest skin-to-skin
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest-to-chest skin-to-skin contact (CC SSC)
Study: 33186312
Drug: Removal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removal of the blocker and actively deflating the cuff before SLMA insertion
Study: 35089607
Drug: Daratumumab in
Normalized name: daratumumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab in combination with pomalidomide and dexamethasone (D‐Pd)
Study: 39719502
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT-AFL) 2 mg
Study: 36207063
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) at 1000-3000 mg
Study: 33404895
Drug: CHF1535 (beclometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF1535 (beclometasone dipropionate 50 μg and formoterol fumarate 6 μg via pMDI)
Study: 33404895
Drug: CHF1535 (beclometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF1535 (beclometasone dipropionate 100 μg and formoterol fumarate 12 μg via pMDI)
Study: 33404895
Drug: CHF1535 (beclometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF1535 (beclometasone dipropionate 200 μg and formoterol fumarate 24 μg via pMDI)
Study: 33404895
Drug: Free combination
Normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination of beclometasone dipropionate and formoterol fumarate
Study: 34736575
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (E2) 1 mg/day plus vaginal progesterone (P4) 45 mg/day for 10 days each month
Study: 39248270
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection
Study: 33745439
Drug: MTX test
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX test (20 mg, 2 × 10 mg capsules)
Study: 33745439
Drug: MTX reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX reference (20 mg, 2 × 10 mg capsules)
Study: 32276315
Drug: 0.7 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)
Study: 32276315
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)
Study: 32276315
Drug: 0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/day (placebo)
Study: 33464336
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of ACEIs or ARBs
Study: 32593173
Drug: 250 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 µg IV Synacthen
Study: 36442353
Drug: Anti-PD-1/PD-L1 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1/PD-L1 therapy
Study: 33567475
Drug: Active arm
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active arm with rescue medication
Study: 35583186
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg (2.5 mg if impaired renal function or concomitant antiplatelet therapy)
Study: 35583186
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (vitamin K antagonist or antiplatelet therapy)
Study: 32698430
Drug: Technological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technological treatment using SonicHand and Riablo™ systems providing auditory and visual biofeedback
Study: 37979717
Drug: Therapeutic-dose heparin
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose heparin
Study: 35099994
Drug: Standard prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylactic or intermediate-dose heparins
Study: 34203925
Drug: Fucoidan (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fucoidan (3.0 g/day from beverages)
Study: 37220815
Drug: Anti-VEGF therapy
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF therapy
Study: 35965109
Drug: 0.11 mg
Normalized name: camphor 0.11 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.11 mg OC-02 SNS
Study: 35965109
Drug: 0.55 mg
Normalized name: coumarin 0.55 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.55 mg OC-02 SNS
Study: 35965109
Drug: 1.1 mg
Normalized name: menthol 1.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 mg OC-02 SNS
Study: 33975710
Drug: Ultra-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dose imaging protocol (ULDP)
Study: 38662661
Drug: Treatment-as-usual (Control)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (Control)
Study: 32034019
Drug: Valacyclovir (dose-titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (dose-titrated from 2g to a targeted oral dose of 4g daily)
Study: 35995640
Drug: Aromatherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy with 40% rose essential oil inhalation for three consecutive nights
Study: 35995640
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water inhalation as placebo
Study: 34656144
Drug: High-dose PXT3003
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose PXT3003 (6/0.70/210 mg)
Study: 34656144
Drug: Low-dose PXT3003
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PXT3003 (3/0.35/105 mg)
Study: 35846221
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment arms
Study: 32249170
Drug: Drug-Coated Balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Coated Balloon (DCB)
Study: 33386751
Drug: Low maternal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low maternal education, poor parents' perception of oral health, non-use of dental services, low frequency of tooth brushing
Study: 37657522
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (control)
Study: 33903855
Drug: Camostat mesilate
Normalized name: Camostat mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat mesilate 200 mg three times daily for 5 days
Study: 36442895
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral therapy
Study: 34562501
Drug: Ozone treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone treatment with no activation (NA)
Study: 35219302
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine 40 ml (medium concentration group)
Study: 35219302
Drug: 0.4% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% ropivacaine 40 ml (low concentration group)
Study: 36853224
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy
Study: 34045378
Drug: Avoid antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoid antiplatelet therapy
Study: 38750866
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg
Study: 36058230
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate 5 mg/day for 24 h plus standard care
Study: 32074369
Drug: Other Analgesics
Normalized name: OTHER ANALGESICS AND ANTIPYRETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Analgesics (OA)
Study: 36273173
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg encapsulated Xanthohumol (XN) per day
Study: 33644992
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI) 80 U twice weekly during a 12-week open-label period, followed by either RCI or placebo for another 12 weeks.
Study: 39666517
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment
Study: 33068178
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (LLLT + 5% minoxidil)
Study: 36099080
Drug: Informative talk
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informative talk supplemented with a 1200-word written information source about the HPV vaccine.
Study: 34523814
Drug: Topical ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular dosing of GLH8NDE at doses of 9, 18, 36 mg (Koreans), and 36 mg (Whites)
Study: 37158925
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 12 weeks
Study: 32588050
Drug: Sodium zirconium
Normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium zirconium cyclosilicate (SZC) 10g TID for 48 hours followed by maintenance therapy with SZC QD for ≤29 days
Study: 32237024
Drug: Antenatal magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal magnesium sulphate (MgSO4) - loading dose of 5 g followed by 1 g/hour
Study: 35987083
Drug: MIACT (Motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIACT (Motivational Interviewing plus Acceptance and Commitment Therapy)
Study: 35987083
Drug: CC (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (Conventional Care)
Study: 33143883
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg kg−1 Cr)
Study: 33143883
Drug: Cr 25
Normalized name: Paxil CR 25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr 25 mg kg−1
Study: 33143883
Drug: Cr 50
Normalized name: Sinemet CR 50mg-200mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr 50 mg kg−1
Study: 33143883
Drug: Cr 100
Normalized name: Luvox CR 100mg Extended-Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr 100 mg kg−1
Study: 35972855
Drug: Islatravir 2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 2.25 mg with doravirine and lamivudine
Study: 32252548
Drug: Dabigatran dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran dual therapy (150 mg)
Study: 32252548
Drug: Dabigatran dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran dual therapy (110 mg)
Study: 34825538
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy for insomnia
Study: 34981829
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg every 2 weeks (Q2W)
Study: 34981829
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg every 4 weeks (Q4W)
Study: 34981829
Drug: Uptitration to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uptitration to Secukinumab 300 mg every 2 weeks (Q2W)
Study: 35934140
Drug: JNJ‐10450232 (NTM‐006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐10450232 (NTM‐006) single doses (50–6000 mg)
Study: 35934140
Drug: JNJ‐10450232 (NTM‐006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐10450232 (NTM‐006) multiple doses (250–2500 mg twice daily for 8 days)
Study: 33278071
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of salbutamol respirable solution nebulized by Aerogen Solo connected to Combihaler spacer with 2 puffs salbutamol MDI (200 µg salbutamol) before nebulisation
Study: 32245781
Drug: High-hemoglobin group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-hemoglobin group (targeting hemoglobin levels of 11-13 g/dl)
Study: 32245781
Drug: Low-hemoglobin group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-hemoglobin group (targeting hemoglobin levels of 9-11 g/dl)
Study: 35970302
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC; salvage chemoimmunotherapy followed by high-dose therapy with autologous stem cell rescue)
Study: 34793718
Drug: 177Lu-Dotatate plus
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-Dotatate plus long-acting octreotide (7·4 GBq every 8 weeks, 30 mg intramuscularly)
Study: 34793718
Drug: High-dose long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose long-acting octreotide (60 mg every 4 weeks)
Study: 35636686
Drug: Succinylcholine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.5 mg/kg
Study: 36246976
Drug: Laparoscopic parapelvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic parapelvic cyst topical decompression
Study: 34591237
Drug: pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 200 mg every 3 weeks
Study: 34591237
Drug: chemotherapy (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy (investigator's choice of paclitaxel, docetaxel, or irinotecan)
Study: 39499492
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy
Study: 34305809
Drug: Regular-dosage therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-dosage therapy
Study: 37493287
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injections
Study: 35915317
Drug: TACE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE plus Cidan Capsule (0.27 g/capsule, 5 capsules every time, 4 times a day for 6 months)
Study: 36002874
Drug: Transcutaneous auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous auricular vagus nerve stimulation (taVNS), two one-hour sessions daily for four weeks at suprathreshold intensities.
Study: 33569570
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg QID elenbecestat
Study: 32729923
Drug: High-nitrate beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-nitrate beetroot juice (∼400 mg nitrate) and folic acid (∼5 mg folic acid) (N + F)
Study: 35511890
Drug: Losartan (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (daily oral starting at 25 mg, increasing every 8 weeks for 6 months)
Study: 39661957
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual
Study: 33471739
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral calcium or calcitriol supplementation (test group)
Study: 35491482
Drug: No β-blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: No β-blockers
Study: 33205280
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg
Study: 35887534
Drug: DehydraTECH2.0 CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: DehydraTECH2.0 CBD formulation
Study: 39636024
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo
Study: 38689310
Drug: Continuous morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine
Study: 32365226
Drug: Temsirolimus (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (25 mg weekly) plus Cetuximab (400/250 mg/m2 weekly)
Study: 33932130
Drug: Midazolam 3
Normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 3 mg
Study: 32030780
Drug: A annua
Normalized name: IVA ANNUA POLLEN
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A annua sublingual immunotherapy (SLIT) for 32 weeks